Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000670968 | SCV000795899 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2017-11-29 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001004142 | SCV001162875 | pathogenic | Usher syndrome type 2A | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV001388593 | SCV001589647 | pathogenic | not provided | 2024-11-11 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln4541*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with USH2A-related conditions (PMID: 22135276, 28559085). ClinVar contains an entry for this variant (Variation ID: 555195). For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV001388593 | SCV002020852 | pathogenic | not provided | 2021-07-05 | criteria provided, single submitter | clinical testing | |
Genetics and Molecular Pathology, |
RCV001004142 | SCV002761651 | pathogenic | Usher syndrome type 2A | 2020-10-07 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003453316 | SCV004183149 | pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001004142 | SCV004183150 | pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003453316 | SCV005055776 | pathogenic | Retinitis pigmentosa 39 | 2023-11-22 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001004142 | SCV002088250 | pathogenic | Usher syndrome type 2A | 2021-02-01 | no assertion criteria provided | clinical testing |